3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
NSCLC
3
Brain Neoplasms
3
Neoplasms
2
Squamous Cell Carcinoma of Lung
1
Non-squamous Non-small Cell Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Non-Small-Cell Lung
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Esophageal Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Radiosurgery
6
Bevacizumab
4
Gentamicins
3
Everolimus
3
Cochlear Implants
3
Lapatinib
2
tozuleristide
1
neratinib
1
icotinib
1
gallium Ga 68 dotatate
1
brigatinib
1
Triamcinolone Acetonide
1
Sufentanil
1
Sirolimus
1
Microsurgery
1
Methylprednisolone
1
Magnetic Resonance Spectroscopy
1
Losartan
1
Head Movements
1
HDAC-42
1
Fluoresceins
1
Fluorescein
1
Exome
1
Endostatins
1
Endoscopes
1
Docosahexaenoic Acids
1
Decision Support Techniques
1
Axitinib
1
Aspirin
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroma, Acoustic
×
icotinib
×
Clear all
NCT02934256
2021-09-09
Icotinib
Beijing Tiantan Hospital
Phase 2
Completed
10 enrolled